Jupiter Life Line Hospitals
Book Building issueMainboard₹869 Cr issue
+30.61%
Listing gain over issue price
Issue size
₹869 Cr
1 lot at cut-off
₹14,700
Lot size
20shares
Open
06 Sep 2023
Close
08 Sep 2023
Allotment
13 Sep 2023
Listing
18 Sep 2023
Listing performance
Issue price
₹735
Listed at
₹960
Listing-day close
₹1,075.75
Latest price
—
Listing gain
+30.61%
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Issue details
- IPO date
- 06 Sep 2023 – 08 Sep 2023
- Listing date
- 18 Sep 2023
- Face value
- ₹10 per share
- Issue price
- ₹735 per share
- Lot size
- 20 shares
- Issue type
- Book Building issue
- Total issue size
- ₹869 Cr
- Market cap at offer price
- ₹4,819 Cr
- Promoter holding
- 49.79% → 40.91% pre-issue → post-issue
- ISIN
- INE682M01012
- Registrar
- Kfin Technologies Ltd.
- Lead managers
- ICICI Securities Ltd.
- Registered office
- 1004, 10th Floor, 360 Degree Business Park, Maharana Pratap Chowk, LBS Marg, Mulund (West), Maharashtra
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 35,47,247 | — | — |
| Market maker | 0 | — | — |
Application size
Minimum 20 shares per lot, in multiples, at ₹735
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 20 | ₹14,700 |
| Retail (max) | 13 | 260 | ₹1,91,100 |
| S-HNI (min) | 14 | 280 | ₹2,05,800 |
| S-HNI (max) | 68 | 1,360 | ₹9,99,600 |
| B-HNI (min) | 69 | 1,380 | ₹10,14,300 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Shares allocated
35,47,247
Anchor portion
₹261 Cr
at ₹735 per share
Valuation and performance
Valuation at offer price
₹735 per share
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 13.95 | — |
| P/E (×) | 52.69 | — |
| Market cap | — | ₹4,819 Cr |
Key performance indicators
Latest reported period
- Return on net worth
- 20.03%
- ROCE
- 20.94%
- PAT margin
- −0.47%
- NAV per share
- ₹64.39
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Jupiter Life Line Hospitals
Jupiter Life Line Hospitals Limited is a corporate healthcare provider headquartered in Mumbai, Maharashtra, incorporated in 2002 and commenced operations in December 2002. The company operates three hospitals under the 'Jupiter' brand in Thane, Pune, and Indore with a total bed capacity of 1,194 beds as of March 31, 2023, and is developing a 500+ bed multi-specialty hospital in Dombivli. The company has been operating for over 15 years as a quaternary care provider in western India. Revenue comes primarily from inpatient and outpatient hospital services, with fiscal 2023 revenue from operations of ₹8,925.43 million. The company serves diverse payers including self-payers (45.33% of hospital service income), insurance companies and corporations (53.35%), and government schemes (1.32%).
Company Analysis
from RHPJupiter Life Line Hospitals Limited operates multi-specialty tertiary and quaternary healthcare facilities across western India, providing hospital and diagnostic services through three operational hospitals and a planned expansion.
Jupiter Life Line Hospitals Limited is a corporate healthcare provider headquartered in Mumbai, Maharashtra, incorporated in 2002 and commenced operations in December 2002. The company operates three hospitals under the 'Jupiter' brand in Thane, Pune, and Indore with a total bed capacity of 1,194 beds as of March 31, 2023, and is developing a 500+ bed multi-specialty hospital in Dombivli. The company has been operating for over 15 years as a quaternary care provider in western India. Revenue comes primarily from inpatient and outpatient hospital services, with fiscal 2023 revenue from operations of ₹8,925.43 million. The company serves diverse payers including self-payers (45.33% of hospital service income), insurance companies and corporations (53.35%), and government schemes (1.32%).
Tertiary and quaternary healthcare servicesHospital operationsInpatient and outpatient care
Objects of the Issue
- Repayment/pre-payment, in full or part, of borrowings availed from banks by our Company and Material Subsidiary ₹5,101.55 million p.27
- General corporate purposes ₹11.63 million p.27
- Repayment/pre-payment, in full or part, of borrowings availed from banks by our Company and Material Subsidiary ₹5,101.55 million p.106
- General corporate purposes ₹11.63 million p.106
- Funding capex for the new Dombivli hospital construction p.207
- General corporate purposes and working capital p.210
Issue Structure
- Total Issue
- ₹8,690.76 million (11,824,163 equity shares)
- Fresh Issue
- ₹5,420.01 million (7,374,163 equity shares)
- Offer for Sale
- ₹3,270.75 million (4,450,000 equity shares)
- Price Band
- ₹695 to ₹735 per equity share
- Lot Size
- 20 equity shares and in multiples of 20 equity shares
- Face Value
- ₹10 per equity share
Business Model
The company generates revenue from hospital and diagnostic services provided through its three operational hospitals. Revenue streams include inpatient and outpatient services, with income from hospital services comprising 99% of revenue from operations. The company derives significant revenue from insurance companies, third-party administrators, and corporations (53.35% of hospital service income in fiscal 2023). The business model focuses on providing advanced tertiary and quaternary healthcare services at competitive pricing to maintain high patient volume and occupancy rates.
Business Segments
Multi-specialty tertiary and quaternary healthcare provider
Multi-specialty tertiary and quaternary healthcare provider
Multi-specialty tertiary and quaternary healthcare provider, acquisition completed November 15, 2020
Inpatient hospital services including bed rentals, consultancy, diagnostics, pathology lab services, consumables, and surgery costs provided to patients requiring overnight stay
Outpatient department services including consultancy, day surgeries, and diagnostics and pathology lab services for patients not requiring overnight stay
Multi-specialty tertiary and quaternary care hospital with over 30 key specialties including organ transplant, oncology, cardiology, orthopaedics, and neuro-rehabilitation services
Multi-specialty tertiary and quaternary care hospital with over 30 key specialties including cardiology, oncology, orthopaedics, and robotic surgery capabilities
Multi-specialty tertiary care hospital with key specialties including organ transplant, oncology, cardiology, orthopaedics, and neuro-rehabilitation services
Inpatient and outpatient hospital services including charges for accommodation, operation theatre, medical professional services, equipment, radiology, laboratory and pharmaceutical goods used in patient treatments
Sale of pharmacy goods through Jupiter Pharmacy partnership firm
Diagnostic imaging and laboratory services through group companies
Fortune Park Lake City Hotel operating in Thane under management collaboration with ITC group for promoting medical tourism
Inpatient hospital services including accommodation, operation theatre, medical professional services, equipment, radiology, laboratory services
Outpatient hospital services including medical consultations and diagnostic services
Hotel operations at hospital facilities
SWOT Analysis
Strengths
- • Established multi-specialty healthcare provider with 15+ years of operating history(p.26)
- • Significant revenue growth trajectory across fiscal periods(p.28)
- • Expanding bed capacity and operational scale(p.26)
- • Growing profitability recovery post-pandemic(p.28)
- • Improving occupancy rates indicating operational efficiency gains(p.40)
- • Experienced medical professionals and management team(p.54)
- • Expanding doctor capacity to support growing patient volumes(p.49)
- • Growing revenue demonstrating operational scale(p.73)
- • Strong profitability growth trajectory(p.73)
- • Registered intellectual property and brand recognition(p.52)
- • Geographic expansion with acquisition of Indore hospital(p.59)
- • Insurance coverage to mitigate operational risks(p.51)
- • Established multi-specialty tertiary/quaternary healthcare provider with 15+ year track record(p.123)
- • All-hub-no-spoke model focused on quality patient care with modern infrastructure(p.123)
- • Strong ability to attract and retain skilled healthcare professionals(p.123)
- • Proven track record of operational and financial performance with diversified revenue(p.123)
- • Experienced professional management team with ESG focus(p.123)
- • Strong financial metrics with 20%+ RoNW and 23.45% EBITDA margin in FY2023(p.130)
- • Among key multi-specialty tertiary and quaternary healthcare providers in MMR and western India with strong 15+ year track record(p.199)
- • Diverse revenue streams with low dependence on government schemes(p.202)
- • Consistent financial and operational growth with strong EBITDA margins(p.205)
- • Patient-centric infrastructure with over 1,000 sq ft per bed and advanced technology(p.203)
- • Ability to attract skilled healthcare professionals with low doctor attrition(p.204)
- • Strong occupancy rates and ARPOB growth trajectory(p.205)
- • Freehold ownership of all hospital properties eliminating lease risk(p.202)
- • Lowest material and consumable costs among peer hospitals(p.196)
- • Established multi-specialty hospital network with significant operational bed capacity(p.276)
- • Experienced and qualified management team with significant healthcare industry tenure(p.237)
- • Strong revenue growth trajectory and profitability improvement(p.272)
- • Diversified revenue streams including hospital services, pharmacy, and hospitality(p.276)
- • Multi-specialty tertiary and quaternary healthcare provider with significant scale(p.311)
- • Strong operational performance and growing patient volumes(p.313)
- • Improving occupancy rates demonstrating operational efficiency(p.314)
- • Strong and growing profitability(p.325)
- • Improving EBITDA margins(p.332)
- • Comprehensive specialization across 30+ specialties(p.311)
- • Accreditation and recognition of quality standards(p.312)
Weaknesses
- • Heavy dependence on single largest revenue generator creates concentration risk(p.35)
- • High attrition rates among nursing and professional staff(p.35)
- • Subsidiaries reporting operating losses and negative cash flows(p.43)
- • Occupancy rates lag significantly behind listed peer hospitals(p.48)
- • Unresolved land-related PIL threats to flagship hospital operations(p.37)
- • Dependence on senior management for operations(p.54)
- • Rising doctor-patient ratio reducing service quality(p.49)
- • Contingent liabilities from pending litigation(p.55)
- • Trademark ownership concentration with promoters(p.52)
- • Insurance coverage may be insufficient for all claims(p.50)
- • Significant debt obligations requiring servicing(p.73)
- • Regulatory compliance gaps in past equity share allotments(p.57)
- • Non-compliance with CSR spending obligations(p.59)
- • Significant financial leverage with borrowings of ₹5,101.55 million to be repaid from IPO proceeds(p.107)
- • High concentration of net proceeds (94%) directed solely to debt repayment(p.106)
- • Limited cash generation for growth investment post-IPO(p.106)
- • Heavy dependence on collateralized lending with 51% equity pledge requirements(p.109)
- • High nurse attrition rate relative to doctors(p.204)
- • Lower average occupancy rate at Indore hospital compared to Thane and Pune(p.205)
- • Smaller bed capacity relative to key competitors(p.188)
- • Concentration of revenue in Thane hospital(p.205)
- • Significant debt burden with high borrowings relative to equity(p.271)
- • Material subsidiary (Jupiter Hospital Projects) with consistent operating losses and negative net worth(p.231)
- • High finance costs impacting profitability(p.272)
- • Concentration of operational assets and patient base in limited geographic locations(p.276)
- • Significant debt burden with high leverage ratio(p.331)
- • High professional fees as percentage of expenses(p.315)
- • Newly acquired Indore hospital still in gestation period with low occupancy(p.315)
- • Contingent liabilities from pending litigation(p.331)
- • Concentration of significant shareholding among promoters(p.296)
Opportunities
- • Strong market growth trajectory in West India healthcare delivery sector(p.26)
- • Planned expansion into Dombivli with 500+ bed capacity hospital(p.26)
- • Favorable structural tailwinds from health insurance penetration growth(p.26)
- • Strategic expansion capacity in underserved West India markets(p.41)
- • High health insurance penetration in western India markets(p.56)
- • Growing healthcare demand from rising incomes(p.56)
- • Capacity for geographic expansion through acquisitions(p.59)
- • Improved operational efficiency and profitability(p.58)
- • Healthcare delivery market in India projected to grow at 11.3% CAGR to ₹8.6 trillion by FY2027(p.161)
- • Western India healthcare market expected to grow at 14-16% CAGR to ₹2.15-2.25 trillion by FY2027(p.162)
- • Ayushman Bharat expanding health insurance penetration with 229.8 million cards created(p.165)
- • Rising income levels increasing affordability and demand for quality healthcare(p.169)
- • Increasing non-communicable diseases driving demand for tertiary/quaternary care(p.151)
- • Low penetration of chained hospitals in West India provides expansion opportunity(p.162)
- • Aging demographic with 60+ population growing to 13% by 2026 increasing healthcare needs(p.168)
- • Expansion into underserved tier 2 and 3 locations with low bed density in western India(p.207)
- • Healthcare market in western India expected to grow 14-16% CAGR to ₹2.15-2.25 trillion by 2027(p.207)
- • High health insurance penetration in western India at 78% vs 38% national average creating demand pull(p.202)
- • Planned Dombivli hospital with 500 beds in densely populated micro-market(p.207)
- • Strategic inorganic growth through acquisitions in focus micro-markets(p.207)
- • Leveraging brand for medical tourism in tier-1 cities with international connectivity(p.172)
- • Expansion of hospital network in underserved markets through acquisitions(p.276)
- • Growth in medical tourism and hospitality services(p.276)
- • Scaling of ancillary healthcare services and diagnostic capabilities(p.276)
- • Expansion through new Dombivli hospital with 500+ bed capacity(p.311)
- • Growth in hospital services as recovery from COVID-19 accelerates(p.325)
- • Increasing patient volumes and market opportunity in western India(p.312)
- • Potential for higher revenue per patient through service mix optimization(p.314)
- • Economies of scale through network expansion(p.316)
Threats
- • Regulatory changes and compliance uncertainty in healthcare sector(p.43)
- • Intense competition from established pan-India hospital chains(p.47)
- • Dependence on third-party payers with termination/renewal risks(p.42)
- • Vulnerability to supply chain disruptions and input cost pressures(p.42)
- • Persistent high cost structure limits pricing flexibility(p.37)
- • Changing tax and regulatory environment(p.62)
- • Dependence on Indian economic conditions(p.62)
- • Medical malpractice and litigation risks(p.50)
- • Communicable disease risks in hospital operations(p.53)
- • Fire and safety hazards from hazardous materials(p.53)
- • Labour unrest and unionization risks(p.54)
- • Stringent labour law compliance requirements(p.54)
- • Competition Act enforcement and scrutiny(p.64)
- • COVID-19 pandemic impact on hospital operations(p.55)
- • Low health insurance penetration outside western India(p.56)
- • Regulatory license renewal and approval risks(p.49)
- • Global financial instability affecting Indian markets(p.64)
- • India's healthcare spending lags peers at only 3.0% of GDP vs developed countries(p.143)
- • High out-of-pocket expenditure burden at 51% of current health spending creates affordability pressure(p.143)
- • Acute shortage of healthcare infrastructure with bed density of only 15 per 10,000 population(p.144)
- • Critical shortage of healthcare personnel with only 7 physicians per 10,000 population(p.145)
- • Regulatory uncertainty regarding utility of Net Proceeds with no independent appraisal(p.107)
- • Risk from equity share pledging requirements limiting promoter flexibility(p.104)
- • Intense competition from established pan-India hospital chains and regional players(p.216)
- • Government price capping on medical devices may compress margins(p.175)
- • Outstanding receivables from government schemes affecting cash flow(p.175)
- • Paucity of experienced specialized doctors creating operational constraints(p.175)
- • Highly regulated industry requiring multiple licenses, permits and accreditations(p.217)
- • Risk of medical malpractice litigation impacting reputation and finances(p.216)
- • Healthcare industry cyclicality and macroeconomic sensitivity affecting patient volumes and reimbursement rates(p.265)
- • Regulatory changes in healthcare delivery and reimbursement frameworks(p.281)
- • Competitive pressure from other multi-specialty and specialty hospitals(p.264)
- • Dependence on key managerial personnel and founder-led management structure(p.258)
- • Highly regulated healthcare industry with price control restrictions(p.316)
- • Risk of regulatory actions against power generation arrangements(p.339)
- • Exposure to pending public interest litigations regarding land use and FSI(p.339)
- • COVID-19 pandemic impact on patient volumes and operations(p.316)
- • Competition from other healthcare providers in western India(p.313)
- • Rising labour and operating costs in healthcare industry(p.315)
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Dr. Ajay Thakker | Promoter | 13,597,829 shares (23.37%) | 13,597,829 shares (20.74%) |
| Dr. Ankit Thakker | Promoter | 4,375,789 shares (7.52%) | 4,375,789 shares (6.67%) |
| Western Medical Solutions LLP | Promoter | 5,703,797 shares (9.80%) | 5,703,797 shares (8.70%) |
| Devang Vasantlal Gandhi (HUF) | Promoter Group Selling Shareholder | 1,250,000 shares (2.15%) | 0 shares (0%) |
| Devang Gandhi jointly with Neeta Gandhi | Promoter Group Selling Shareholder | 1,310,000 shares (2.25%) | 410,000 shares (0.63%) |
| Dr. Ajay Thakker | Promoter | 23.37% | 20.74% |
| Western Medical Solutions LLP | Promoter | 9.80% | 8.70% |
| Dr. Ankit Thakker | Promoter | 7.52% | 6.67% |
| Dr. Ajay Thakker | Promoter | 23.37% | — |
| Dr. Ankit Thakker | Promoter | 7.52% | — |
| Dr. Ajay Thakker | Founder, Chairman and Managing Director | — | — |
| Dr. Ajay Thakker | Promoter | 23.37% | — |
| Dr. Ankit Thakker | Promoter | 7.52% | — |
| Western Medical Solutions LLP | Promoter | 9.80% | — |
| Dr. Ajay P Thakker | Promoter | 19.68% | — |
| Dr. Ankit Thakker | Promoter | 5.60% | — |
| Western Medical Solutions LLP | Promoter | 10.09% | — |
| Devang Vasantlal Gandhi (HUF) | Selling Shareholder | — | — |
| Devang Gandhi and Neeta Gandhi | Selling Shareholder | — | — |
| Nitin Thakker and Asha Thakker | Selling Shareholder | — | — |
| Modi Family Private Trust | Selling Shareholder | — | — |
| Bhaskar P Shah (HUF) | Selling Shareholder | — | — |
| Rajeshwari Capital Market Limited | Selling Shareholder | — | — |
| Vadapatra Sayee Raghavan (HUF) | Selling Shareholder | — | — |
| Sangeeta Ravat and Dr. Hasmukh Ravat | Selling Shareholder | — | — |
| Dr. Hasmukh Ravat and Sangeeta Ravat | Selling Shareholder | — | — |
| Shreyas Ravat and Sangeeta Ravat | Selling Shareholder | — | — |
Leadership
Dr. Ajay Thakker · Chairman and Managing Director
Dr. Ankit Thakker · Executive Director and Chief Executive Officer
Harshad Purani · Chief Financial Officer
Suma Upparatti · Company Secretary and Compliance Officer
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.
Jupiter Life Line Hospitals IPO FAQs
What is the lot size of Jupiter Life Line Hospitals IPO?
The minimum lot size of Jupiter Life Line Hospitals IPO is 20 shares. One lot costs ₹14,700 at the cut-off price.
When does Jupiter Life Line Hospitals IPO open and close?
Jupiter Life Line Hospitals IPO opened for subscription on 06 Sep 2023 and closed on 08 Sep 2023.
What is the listing date of Jupiter Life Line Hospitals IPO?
Jupiter Life Line Hospitals IPO listed on 18 Sep 2023.